Morgan Stanley Cin Cor Pharma, Inc. Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$10.75 - $29.84 $532,619 - $1.48 Million	-49,546 Reduced 64.56%	27,204 $334,000
Q3 2022 Nov 14, 2022	BUY	$19.9 - $38.94 $1.07 Million - $2.09 Million	53,667 Added 232.5%	76,750 $2.52 Million
Q2 2022 Oct 27, 2022	BUY	$13.67 - $25.74 $273,946 - $515,829	20,040 Added 658.56%	23,083 $434,000
Q2 2022 Aug 15, 2022	BUY	$13.67 - $25.74 $273,946 - $515,829	20,040 Added 658.56%	23,083 $434,000
Q1 2022 Oct 27, 2022	SELL	$14.13 - $28.49 $283,165 - $570,939	-20,040 Reduced 86.82%	3,043 $53,000
Q1 2022 May 13, 2022	BUY	$14.13 - $28.49 $42,997 - $86,695	3,043 New	3,043 $53,000

Ticker CINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,764,300
Description
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.